États-Unis · Plateformes & données · Finviz

UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

Publié par Finviz · États-Unis il y a 10 h

Supported The Michael J Fox Foundation for Parkinson's Research, Alzheimer's Research UK and LifeArc, the study targets earlier detection, prevention and treatment of Parkinson’s…

Lire l'article complet sur Finviz Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finviz.com)

UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

À lire aussi

BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 52-Week Low - Here's What Happened

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

Partager

À lire aussi

BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 52-Week Low - Here's What Happened

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows